TriSalus Life Sciences, Inc. (TLSI)

Market Cap	203.57M
Revenue (ttm)	32.14M
Net Income (ttm)	-30.31M
Shares Out	37.84M
EPS (ttm)	-1.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46,348
Open	5.50
Previous Close	5.19
Day's Range	5.50 - 5.50
52-Week Range	3.50 - 6.08
Beta	0.47
Analysts	Strong Buy
Price Target	10.90 (+98.18%)
Earnings Date	Aug 13, 2025

About TLSI

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinic...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 110
• Stock Exchange: NASDAQ
• Ticker Symbol: TLSI
• Website: https://trisaluslifesci.com

Financial Performance

In 2024, TriSalus Life Sciences's revenue was $29.43 million, an increase of 58.99% compared to the previous year's $18.51 million. Losses were -$33.23 million, -47.75% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for TLSI stock is "Strong Buy." The 12-month stock price forecast is $10.9, which is an increase of 98.18% from the latest price.

Price Target

$10.9

(98.18% upside)

Analyst Consensus: Strong Buy